Latest From Maxygen Inc.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.
US Inhaled CNS drug biotech Alexza looks set to be acquired by Spain’s Ferrer, the licensee of its only marketed product Adasuve outside of the US, in an all-cash offer that includes contingent value rights.
Ocera Therapeutics, a clinical-stage biopharmaceutical company focused on acute and chronic orphan liver diseases, has promoted Michael Byrnes to chief financial officer. Mr Byrnes has served as vice president, finance at Ocera since June 2014. Prior to joining Ocera, Mr Byrnes held a variety of corporate finance and accounting roles, most recently serving as corporate controller of Maxygen.
Alejandro Zaffaroni, the biotechnology entrepreneur and Silicon Valley legend who co-founded a number of firms including Alexza, Affymetrix and Alza, has died aged 91 at his home in Atherton, California. The cause was complications of dementia, his assistant Ana Leech confirmed to the New York Times.
Drug Discovery Tools
- Large Molecule
- Drug Discovery Tools
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Musculoskeletal & Connective Tissue Disorders
- North America
- Parent & Subsidiaries
- Maxygen Inc.
- Senior Management
James Sulat, CEO
Lawrence Briscoe , SVP, CFO
Elliot Goldstein, MD, COO & CMO
- Contact Info
Phone: (650) 298-5300
301 Galveston Dr.
Redwood City, CA 94063
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.